No, GLP-1 receptor agonists are not FDA-approved for joint pain treatment
53 Dimitrova, A
Suggested mechanisms for fatigue include imbalances in energy production caused by increased energy requirement (e.g., caused by tumor growth, infection, fever, or surgical procedures), reduced availability of substrates (e.g., due to anorexia, nausea, or vomiting), atypical generation of compounds that disrupt metabolic homeostasis or regular functions of muscles (e.g., cytokines and proteolysis inducers), anemia, and hypoxemia
Anti-obesity drugs should be offered as initial treatment of overweight and obesity for adults with weight-related comorbidities and for those at high risk of complications, and as a component of first-line treatment for patients with obesity and overweight without comorbidities
Nat Commun 11(1):1896